Mutation Specific Kinase activity Measurements
Profiling Kinase Conformations
KinCon biolabs is a biotech startup based in Innsbruck Austria.
We are creating unique biosensors for improved kinase-inhibitor development.
The luciferase based KinCon biosensor measures drug-driven effects on kinase-activity by reflecting changes of cellular kinase conformations.
This technology allows reliable profiling of potential kinase inhibitors under physiological conditions:
- Direct measurement in living cells
- Cancer drug profiling in real-time
- Simple integration of patient mutations for precision medicine
Our vision is to improve drug development of kinase-targeted drugs through mutation-specific activity profiling with our live-cell biosensor platform.
Meet the people working to provide you with new tools to assess kinase drug efficacy.
CSO | co founder
Recent Publications in which the KinCon technology is applied
KinCon biolabs GmbH is a University of Innsbruck spin-off company supported by funding from the Austrian Research Promotion Agency (FFG) Spin-off Fellowship and Austria Wirtschaftsservice (AWS) Preseed program.